Eli Lilly's Zepbound is set to dominate the global obesity market, offering new hope with its groundbreaking treatment for weight management.
Eli Lilly's Zepbound holds potential to dominate obesity market
Go to source). It has been a year since the launch of Zepbound (tirzepatide) for obesity, and Eli Lilly’s competition with Novo Nordisk continues.
Reversing Weight Loss: Breakthrough in Halting Eli Lilly's Tirzepatide Effects
Weight loss drugs like Wegovy and Ozempic have also caused weight regain, sparking concerns among health insurers over the costly long-term coverage of these drugs.
Weight loss drugs like Wegovy and Ozempic have also caused weight regain, sparking concerns among health insurers over the costly long-term coverage of these drugs.
‘#Obesity Market Shift? #Eli_Lilly's #Zepbound could overtake #Novo_Nordisk's #Wegovy as the dominant player.’
“From the start, Zepbound emerged as the primary new competitor of Wegovy, and it seems that Eli Lilly has followed in some way Novo Nordisk’s strategy to increase patients’ population through investigating the drug in multiple indications,” said Costanza Alciati, pharma analyst at GlobalData. Recently, Eli Lilly announced the results from its SURMOUNT-5 trial, comparing Zepbound and Wegovy’s efficacy on equal grounds. Zepbound Drug
Zepbound, as expected, was more effective in promoting weight loss. While Wegovy caused an average weight loss of 13.7 percent body weight, Zepbound promoted around 20.2 percent body weight loss in patients. On December 20, 2024, tirzepatide also received US FDA approval for obstructive sleep apnea. Tirzepatide is being investigated for four additional indications, including cardiovascular risk factors, chronic kidney disease, and metabolic dysfunction-associated steatohepatitis (MASH).“Indeed, semaglutide is approved for type 2 diabetes, obesity, and cardiovascular risk factors, and is in development for four additional indications, including chronic kidney disease,” said the report. According to GlobalData drugs database, more than 400 companies are actively developing obesity drugs, from discovery to pre-registration candidates. The impact of Wegovy on the obesity market has been huge. Key Opinion Leaders (KOLs) interviewed by GlobalData defined it as “revolutionary”.
Diabetes Drug - Tirzepatide Gets FDA Approval for Weight Loss
Tirzepatide, a diabetes medication, is approved for weight loss management by FDA and is found to be very beneficial when combined with diet and exercise.
Tirzepatide, a diabetes medication, is approved for weight loss management by FDA and is found to be very beneficial when combined with diet and exercise.
Reference:
- Eli Lilly’s Zepbound holds potential to dominate obesity market - (https://www.globaldata.com/media/pharma/eli-lillys-zepbound-holds-potential-dominate-obesity-market-says-globaldata/)
Source-IANS
Quiz on Obesity
“We are indeed much more than what we eat, but what we eat can nevertheless help us to be much more than what we are”. - Adelle Davis There are thousands out there battling ‘the bulge’. With childhood obesity on the rise ...
“We are indeed much more than what we eat, but what we eat can nevertheless help us to be much more than what we are”. - Adelle Davis There are thousands out there battling ‘the bulge’. With childhood obesity on the rise ...
How to Lose Weight?
Slide show which explains obesity causes and tips on how to lose weight. Exercising before breakfast is most effective for weight loss.
Slide show which explains obesity causes and tips on how to lose weight. Exercising before breakfast is most effective for weight loss.
